Axoltis peptide NX210c misses primary endpoints in Phase II ALS trial
The French biotech says blood-brain barrier repair readouts and safety data still support a combination role in amyotrophic lateral sclerosis.
PR
By Priya Raman · Science Reporter
Oct 15 06:57 ETSource: BioXconomy
The wire
- 01Axoltis Pharma reported topline results from the Phase II SEALS trial (NCT06365216) of NX210c, a synthetic cyclized 12-amino-acid peptide, which did not reach its primary clinical endpoints in ALS patients.
- 02ALS has few disease-modifying options, especially for the sporadic form affecting 85-90% of patients, so peptide approaches targeting the blood-brain barrier are closely watched.
- 03CEO Yann Godfrin says secondary readouts suggest barrier repair and a strong safety profile, but that is a company interpretation of a failed trial, and full data have not been published.
From the source
Read at bioxconomy.comBBB repair peptide could hold promise for ALS patients
Axoltis’ drug, NX210c, failed to meet clinical endpoints in a Phase II trial – but the company says other readouts are positive.
